• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » A Single Prescriber Reduces Risk of Overdose in Patients on Opioid and Benzodiazepine

A Single Prescriber Reduces Risk of Overdose in Patients on Opioid and Benzodiazepine

September 25, 2022
Kamron Fariba, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Kamron Fariba, MD. Dr. Fariba, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

REVIEW OF: Chua KP et al, JAMA Netw Open 2021;4(8):e2120353

STUDY TYPE: Retrospective cohort study

When a patient on an opioid needs a benzodiazepine, should the two medications be handled by one prescriber or multiple prescribers? Among patients on opioids, one in five are also prescribed a benzodiazepine, but the combination raises the risk of opioid overdose fatalities four-fold. This study is the first to look at safety outcomes for single vs multiple prescribers. 

Using a database of medical and pharmacy claims, researchers performed a retrospective cohort analysis, identifying patients who had one or more days of opioid-benzodiazepine overlap between January 1, 2017, and December 31, 2018. Ultimately, the cohort included 529,053 patients, ages 12 years and older, with an average age of 61. Researchers determined whether the opioids and benzodiazepines were prescribed by a single clinician or by two or more clinicians. The primary outcome measure was the occurrence of an overdose.

The relative overdose risk, adjusted for prescribing patterns, demographics, and comorbidities, was 1.2 times greater when the opioid-benzodiazepine overlap involved multiple prescribers vs a single prescriber (unadjusted overdose risk was 1.8 times greater), which translates to a 20% increased risk of overdose. 

The main limitation is the study’s design, which cannot prove causation. Also, the cohort was restricted to insured patients, and overdose deaths may have been underreported.

CARLAT TAKE

Opioid and benzodiazepine combinations are risky, but the risk goes down when one clinician monitors both scripts. It’s easier to detect problematic use with that arrangement, particularly when the prescriber is a pain specialist, as they require a higher level of scrutiny, including urine drug screens and pill counts. If you’re concerned about the overdose risk in a patient taking both an opioid and a benzo, arranging for them to get both prescriptions from the same physician is a reasonable option.

General Psychiatry
KEYWORDS benzodiazepine opioids overdose
Kamron Fariba, MD

More from this author
www.thecarlatreport.com
Issue Date: September 25, 2022
SUBSCRIBE NOW
Table Of Contents
A Diet for ADHD
Understanding the Varieties of Depression
The Benzodiazepine-Stimulant Combo: What Could Go Wrong?
Treatment-Resistant Depression
Can CBD Work for PTSD?
Aripiprazole in Depression: The Right Dose
A Single Prescriber Reduces Risk of Overdose in Patients on Opioid and Benzodiazepine
CME Post-Test - Depression, TCPR, October/November 2022
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.